Novartis partners with Harvard on biomaterial systems

23-03-2018

Novartis partners with Harvard on biomaterial systems

wildpixel / iStockphoto.com

Novartis and Harvard University have teamed up to develop Harvard’s proprietary biomaterial systems to deliver cancer immunotherapies.


Novartis, immunotherapy development, pharmaceutical licensing agreement, Harvard partnership, Harvard’s Office of Technology Development, Wyss Institute

LSIPR